{"id":1732,"date":"2019-09-17T20:05:57","date_gmt":"2019-09-17T18:05:57","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1732"},"modified":"2024-01-17T10:01:45","modified_gmt":"2024-01-17T09:01:45","slug":"prett-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/prett-2\/","title":{"rendered":"Preclinical and experimental research in thoracic tumors (PReTT)"},"content":{"rendered":"\n

\n\t\tPreclinical and experimental research in thoracic tumors (PReTT)\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The PReTT group focuses on the study of novel therapeutic strategies in thoracic tumours combining basic molecular and patient-oriented translational research, bioinformatics, and also design and development of investigator-initiated clinical trials. In terms of basic research, we study the mechanisms through which tumour cells die in response to different treatments and stimuli. Analysing the responses both at cell and tumour microenvironment level, including the immune system and metabolic status. On the translational side, our focus is the validation of diagnostic and treatment response biomarkers in order to improve the clinical management of thoracic tumours. At the bioinformatics level, the aim is to improve the stratification of thoracic tumours and the identification of potentially novel treatments tailored to the molecular characteristics of the patient.<\/p>\n

77<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"108-mortcelular-cmunozpinedo-def\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t\u2022 Characterisation of immune-tumour-stroma connections in thoracic tumours to improve therapeutic approaches (Ernest Nadal, Cristina Mu\u00f1oz-Pinedo and Xavier Sol\u00e9)
\n\u2022 Metabolic vulnerabilities of lung cancer and malignant pleural mesothelioma (Cristina Mu\u00f1oz-Pinedo and Ernest Nadal)
\n\u2022 Molecular mechanisms of apoptosis and other forms of cell death induced by metabolic challenges and ischaemia (Cristina Mu\u00f1oz-Pinedo)
\n\u2022 Study of germline and somatic genomic alterations in thoracic tumours in tumour tissue and liquid biopsy (Ernest Nadal and Xavier Sol\u00e9)
\n\u2022 Design and development of clinical trials with a solid scientific rationale (Ernest Nadal)
\n\u2022 Stratification of thoracic tumours based on the computational integration of omic data (Xavier Sol\u00e9 and Ernest Nadal)
\n\u2022 Identification of personalized treatments by integrating large-scale pharmacogenomics data and validated drug-response signatures (Xavier Sol\u00e9)\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

– Aliagas E, Alay A, Mart\u00ednez Iniesta M, Hern\u00e1ndez Madrigal M, Cordero D, Gausachs M, Pros E, Saig\u00ed M, Busacca S, Sharkley AJ, Dawson A, Palmero R, Ruffinelli JC, Padrones S, Aso S, Escobar I, Ramos R, Llatj\u00f3s R, Vidal A, Dorca E, Varela M, S\u00e1nchez C\u00e9spedes M, Fennell D, Mu\u00f1oz Pinedo C, Villanueva A, Sol\u00e9 X, Nadal E. Efficacy of CDK4\/6 inhibitors in preclinical models of malignant pleural mesothelioma. Br. J. Cancer. 2021;125(10):1365-1376. doi:10.1038\/s41416-021-01547-y. IF:7,64.<\/p>\n

– Alay A, Cordero D, Hijazo Pechero S, Aliagas E, Lopez Doriga A, Marin R, Palmero R, Llatjos R, Escobar I, Ramos R, Padrones S, Moreno V, Nadal E, Sole X. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J. Immunother. Cancer. 2021;9(2):doi:10.1136\/jitc-2020-001601. IF:13,75.<\/p>\n

– Soo R, Han JY, Dimopoulou G, Cho BC, Yeo CM, Nadal E, Carcereny E, De Castro J, Sala MA, Bernabe R, Coate L, Provencio M, Campelo RG, Cuffe S, Hashemi S, Fruh M, Ruepp B, Roschitzki Voser H, Stahel R, Peters S. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. Ann. Oncol. 2021;32(7):942-944. doi:10.1016\/j.annonc.2021.04.010. IF:32,98.<\/p>\n

– Montironi C, Munoz Pinedo C, Eldering E. Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. Cancers. 2021;13(2):doi:10.3390\/cancers13020284. IF:6,64.<\/p>\n

– Palmero R, Vilarino N, Navarro Martin A, Nadal E. Induction treatment in patients with stage III non-small cell lung cancer. Transl. Lung Cancer Res. 2021;10(1):539-554. doi:10.21037\/tlcr-20-420. IF:6,50.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

20MAR002. Modulating glycemia to improve benefit of chemoradiotherapy and immunotherapy in Non-Small Cell Lung Carcinoma<\/strong>. Fundaci\u00f3 La Marat\u00f3 de TV3. Budget: 200000. 2020-2023. PI: Mu\u00f1oz Pinedo, Cristina.<\/p>\n

20MEC022. Regulaci\u00f3n de la muerte celular, la secreci\u00f3n de citoquinas y la progresi\u00f3n del c\u00e1ncer de pulm\u00f3n por la ruta de se\u00f1alizaci\u00f3n de estr\u00e9s metab\u00f3lico<\/strong>. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 290400. 2020-2023. PI: Mu\u00f1oz Pinedo, Cristina.<\/p>\n

FIS21087. Nuevas estrategias terap\u00e9uticas en mesotelioma pleural maligno basadas en inmunoterapia y terapias dirigidas a ciclo celular y senescencia celular. Instituto de Salud Carlos III (ISCIII)<\/strong>. Budget: 195415. 2022-2024. PI: Nadal Alforja, Ernest.<\/p>\n

PSJ21032. Estudio mediante secuenciaci\u00f3n masiva de la l\u00ednea germinal en pacientes con c\u00e1ncer de pulm\u00f3n y alteraciones gen\u00f3micas tratables (G-DRIVER)<\/strong>. Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Budget: 20000. 2021-2023. PI: Jove Casulleras, Maria.<\/p>\n

19FIS032. Estudio de Nuevas Estrategias Terap\u00e9uticas en Mesotelioma Pleural Maligno y de la Heterogeneidad Clonal y de la Evoluci\u00f3n Temporal a Nivel Gen\u00f3mico<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 165286. 2019-2022. PI: Nadal Alforja, Ernest.<\/p>\n

2021-057-1. ENSAYO CL\u00cdNICO FASE II DE UN SOLO BRAZO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE BINTRAFUSP ALFA (M7824) EN MESOTELIOMA PLEURAL MALIGNO AVANZADO PREVIAMENTE TRATADO. Fundaci\u00f3n GECP<\/strong>. Budget: 12500. 2021- . PI: Nadal Alforja, Ernest.<\/p>\n

2022-001-1. NIVOLUMAB E IPILIMUMAB M\u00c1S DOS CICLOS DE QUIMIOTERAPIA BASADA EN PLATINO COMO TRATAMIENTO DE PRIMERA L\u00cdNEA PARA PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO (CPNM) ESTADIO IV O RECURRENTE CON MET\u00c1STASIS CEREBRALES SINCR\u00d3NICAS<\/strong>. Fundaci\u00f3n GECP. Budget: 10800. 2021- . PI: Nadal Alforja, Ernest.<\/p>\n

18ACL130. ENSAYO CL\u00cdNICO FASE II, NO RANDOMIZADO EN PRIMERA L\u00cdNEA DE ATEZOLIZUMAB EN COMBINACI\u00d3N CON CARBOPLATINO Y PEMETREXED EN PACIENTES CON C\u00c1NCER DE PULM\u00d3N NO MICROC\u00cdTICO ESTADIO IV CON MET\u00c1STASIS CEREBRALES ASINTOM\u00c1TICAS<\/strong>. Budget: 4000. 2018-2019. PI: Nadal Alforja, Ernest.<\/p>\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

The group has discovered how and why the cells die in conditions with a lack of nutrients<\/p>\n

Proyectos financiados por el Instituto de Salud Carlos III (ISCIII) y cofinanciados por el Fondo Europeo de Desarrollo Regional (FEDER):<\/em><\/p>\n

 <\/p>\n

Se\u00f1alizaci\u00f3n c\u00e9lula-c\u00e9lula y muerte celular en respuesta a la falta de nutrientes y a la inhibici\u00f3n del metabolismo tumoral<\/strong><\/p>\n

PI13\/00139. 01\/2014-09\/2017. 127.500 \u20ac. IP: Cristina Mu\u00f1oz Pinedo.<\/p>\nLas c\u00e9lulas tumorales son dependientes de la glucosa como fuente de energ\u00eda y tambi\u00e9n como fuente del carbono necesario para la producci\u00f3n de macromol\u00e9culas. Por este motivo, y tambi\u00e9n debido a varias mutaciones oncog\u00e9nicas, son m\u00e1s sensibles a la falta de glucosa que las c\u00e9lulas no transformadas. En este proyecto buscamos caracterizar respuestas intr\u00ednsecas a la falta de glucosa y al tratamiento con 2-deoxiglucosa; y mol\u00e9culas secretadas que medien la comunicaci\u00f3n c\u00e9lula-c\u00e9lula en respuesta a estos est\u00edmulos.
\n\"\"\n\t\t\t\t\"Cristina-Mu\u00f1oz-Pinedo22\"\n

\n\t\tMu\u00f1oz Pinedo, Cristina\n\t<\/h4>\n

\n\t\t\n\t\tcmunoz@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Nadal\n

\n\t\tNadal Alforja, Ernest\n\t<\/h4>\n

\n\t\t\n\t\tenadal@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Cristina-Mu\u00f1oz-Pinedo22\"\n

\n\t\tMu\u00f1oz Pinedo, Cristina\n\t<\/h4>\n

\n\t\t\n\t\tcmunoz@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Nadal\n

\n\t\tNadal Alforja, Ernest\n\t<\/h4>\n

\n\t\t\n\t\tenadal@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Ivan-Mac\u00eda-Vidueira\"\n

\n\t\tIvan Mac\u00eda Vidueira\n\t<\/h4>\n

\n\t\t\n\t\timacia@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tRELATED LINKS\n\t<\/h4>\n

\n\t\t\n\t\tFacebook: “Cell Death”\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tApoList archive\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tLab MetaboList archive: Recopilaci\u00f3n\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tMarie Curie network META-CAN\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@meta_canproject\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tDeathBase\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tApored\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@apoptosislab\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@NadalErnest\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers \t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tManagement support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t